Removal Dynamics of Immunoglobulin and Fibrinogen by Conventional Plasma Exchange, Selective Plasma Exchange, and a Combination of the Two

While plasma exchange (PE) can eliminate plasma proteins, including all immunoglobulin (Ig) and coagulation factors, selective plasma exchange (SePE) can retain fibrinogen (Fbg). Here, we investigated the removal dynamics of Ig and Fbg in 53 patients with immunological disorders by PE, SePE, and a combination of the two. When the mean processed plasma volume (PPV) was 0.9 plasma volume (PV), the mean percent reductions of Ig and Fbg by PE were both approximately 62%–65%. When the mean PPV was 1.1 PV, the mean percent reductions by SePE were 53.1% for IgG, 30.1% for IgA, 3.6% for IgM, and 19.0% for Fbg, respectively. In the three plasmapheresis sessions performed on alternate days, we classified treatments into three categories: PE group (PE–PE–PE, N = 2), SePE group (SePE–SePE–SePE, N = 14), and PE/SePE group (PE–SePE–SePE, N = 4). The mean percent reductions of IgG, IgA, IgM, and Fbg were 82.0%, 80.4%, 87.3%, and 80.9%, respectively, for the PE group; 76.4%, 57.7%, 43.3%, and 35.9%, respectively, for the PE/SePE group; and 75.4%, 50.6%, 3.2%, and 29.3%, respectively, for the SePE group. Plasmapheresis modalities can be combined according to clinical conditions, for instance, to achieve both the unspecific removal of pathogens by PE and retention of coagulation factors, such as Fbg, by SePE.

[1]  T. Okado,et al.  Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[2]  T. Yasuda,et al.  Efficacy of Tryptophan Immunoadsorption Plasmapheresis for Neuromyelitis Optica in Two Cases , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  A. Kobsar,et al.  The effect of immunoadsorption with the Immusorba TR‐350 column on coagulation compared to plasma exchange , 2015, Vox sanguinis.

[4]  W. Druml,et al.  Fibrinogen Reduction and Bleeding Complications in Plasma Exchange, Immunoadsorption and a Combination of the Two , 2014, Blood Purification.

[5]  T. Okado,et al.  Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  M. Nangaku,et al.  The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[7]  T. Rai,et al.  Solute Removal Capacity of High Cut‐Off Membrane Plasma Separators , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[8]  C. Yücesan,et al.  Therapeutic plasma exchange in treatment of neuroimmunologic disorders: review of 92 cases. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[9]  D. Barz,et al.  Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation , 2012, Transfusion Medicine and Hemotherapy.

[10]  B. Mcleod Plasma and plasma derivatives in therapeutic plasmapheresis , 2012, Transfusion.

[11]  N. Hanafusa Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[12]  H. Satonaka,et al.  Virus Removal and Eradication by Modified Double Filtration Plasmapheresis Decreases Factor XIII Levels , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[13]  M. Seishima,et al.  Decreased Factor XIII Activity in a Patient With Subcutaneous Bleeding After Double Filtration Plasmapheresis , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[14]  A. Kaplan Therapeutic plasma exchange: core curriculum 2008. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  M. Ogino,et al.  Tryptophan‐immobilized Column‐based Immunoadsorption as the Choice Method for Plasmapheresis in Guillain–Barré Syndrome , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[16]  Noriko Hirata,et al.  Plasma Separator Plasmaflo OP , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[17]  H. Tsuda,et al.  The effectiveness of intravenous human immunoglobulin treatment after plasmapheresis in restoring serum immunoglobulin levels: a preliminary study. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[18]  I. Kanazawa,et al.  Guillain–Barré syndrome with IgM antibody to the ganglioside GalNAc–GD1a , 2001, Journal of Neuroimmunology.

[19]  S. Chevret,et al.  Plasma exchange morbidity in Guillain‐Barré syndrome: Results from the French prospective, double‐blind, randomized, multicenter study , 1993 .

[20]  S. Cook,et al.  Anti-GM1 IgA antibodies in Guillain-Barré syndrome , 1992, Journal of Neuroimmunology.